N/A N=50 Dario Blood Glucose Monitoring System - Android Devices Altitude Evaluation Study
Diabetes Mellitus
Primary: Number of Successful Glucose Readings — 449 Number of Glucose readings in range
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S
MERS (Middle East Respiratory Syndrome)
Primary: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol — 10; 10 Participants
Phase 3 N=444 AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
Osteoarthritis, Knee
Primary: WOMAC Pain Sub-score — -26.49; -27.33; -22.73 score on a scale
N/A N=368 Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses
Myopia
Primary: Symptoms and Complaints — 83.2; 83.6; 78.1; 74.6 score on a scale
Phase 2 N=246 Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
Geographic Atrophy
Primary: Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12 — 0.26; 0.28; 0.35 mm
Phase 4 N=1 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
Bipolar Depression
Primary: Montgomery Asberg Depression Rating Scale — 34 units on a scale
N/A N=35 Evaluation of Ocular Comfort With ISTA Tears vs Systane
Dry Eye Disease
Primary: Percentage of Participants With Preference for One of the Treatments — 23; 1; 11 Participants
Phase 4 N=121 Emotional and Cognitive Control in Late-Onset Depression
Depression
Primary: Change in Depression Severity (Measured by Montgomery Asberg Depression Rating Scale) — 25.26; 1.03; 13.78; 1.08 score on a scale — p=< 0.025
N/A N=441 Evaluation of Two Daily Disposable Contact Lenses.
Myopia
Primary: Percentage of Eyes With > Grade 2 Slit Lamp Findings — 0; 0 eyes
N/A N=257 Epidural Catheter Thread Between Two Different Vendors
Labor Pain
Primary: Number of Participants Who Experienced a Successful Thread at First Pass — 81; 117 Participants — p=<0.0001
Phase 2 N=69 Cabozantinib for Advanced Urothelial Cancer
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants
Phase 2 N=21 Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Least Square (LS) Mean Change From Baseline in 28 Joint Disease Activity Score Using C-Reactive Protein (DAS28-CRP) at Day 15 — -1.931; -2.403 score on a scale — p=0.315
Phase 3 N=44 Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients
Psoriatic Arthritis
Primary: Dactylitis Severity Score (DSS) — -2; -5 change of score on a scale — p==0.026
Phase 4 N=37 Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Endometriosis · Infertility
Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants
Phase 3 N=1,125 Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Percent Change in the Number of Inflamed Lesions (Papules/Pustules)- Time Frame: Baseline to 12 Weeks — -66.22; -72; -16.02 % mean change from baseline